VBIV VBI Vaccines Inc.

1.74
+0.02  (+1%)
Previous Close 1.72
Open 1.71
Price To Book 2.2
Market Cap 169378172
Shares 97,343,777
Volume 105,492
Short Ratio
Av. Daily Volume 698,812

SEC filingsSee all SEC filings

  1. 8-K - Current report 19584460
  2. 8-K - Current report 19568576
  3. 8-K - Current report 19528705
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 181252896
  5. 8-K - Current report 181246327

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

DSMB recommended trial to continue - February 7, 2019. Phase 1/2a six-month PFS and OS data due 1H 2019.
VBI-1901
Recurrent glioblastoma multiforme (rGBM)
Phase 3 data due mid-2019.
Sci-B-Vac - PROTECT
Hepatitis B vaccine
Phase 2 trial to be initiated YE 2019.
VBI-1501
Congenital Cytomegalovirus (CMV)
Phase 3 data due YE 2019.
Sci-B-Vac - CONSTANT
Hepatitis B vaccine

SEC Filings

  1. 8-K - Current report 19584460
  2. 8-K - Current report 19568576
  3. 8-K - Current report 19528705
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 181252896
  5. 8-K - Current report 181246327
  6. 8-K - Current report 181243173
  7. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181237108
  8. 8-K - Current report 181236566
  9. 424B5 - Prospectus [Rule 424(b)(5)] 181236562
  10. 424B5 - Prospectus [Rule 424(b)(5)] 181231068